top of page
Executive Spotlights

BeiGene finalizes a $1.3B Agreement with Ensem for the CDK2 Inhibitor

Cambridge, MA, November 21, 2023 (MSN) -- BeiGene secures global licensing for Ensem Therapeutics' oral cyclin-dependent kinase-2 (CDK2) inhibitor aimed at breast cancer treatment. The deal involves an undisclosed upfront payment to Ensem, with potential milestone payments totaling up to $1.33 billion, along with tiered royalties.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page